Table 1.
Samples | Total reads | Q20 (%) | Q30 (%) | Mapped reads | Mapping rate (%) |
---|---|---|---|---|---|
C1 | 49,013,376 | 97.68 | 93.60 | 46,836,934 | 95.56 |
C2 | 43,642,098 | 97.43 | 93.10 | 41,485,719 | 95.06 |
C3 | 47,105,588 | 97.46 | 93.20 | 44,747,589 | 94.99 |
EY1 | 46,217,576 | 97.48 | 93.22 | 43,778,467 | 94.72 |
EY2 | 47,759,520 | 97.48 | 93.22 | 45,242,692 | 94.73 |
EY3 | 41,839,420 | 97.59 | 93.45 | 39,865,629 | 95.28 |
Average | 45,929,596 | 97.52 | 93.30 | 43,659,505 | 95.06 |
C1, C2, and C3 represent the three biological replicates of the control; EY1, EY2, and EY3 represent the three biological replicates of ethephon treatment.